FinanancingATB Therapeutics raises €54m in Series A financingBelgian ADC specialist ATB Therapeutics BV has kicked off with €54m from EQT Life Sciences and MRL Ventures Fun to push its payload technology towards clinical development. more ➔
Innate Pharma SAAntibody engineeringTetraspecific B/NK cell better than T cell engagersInnate Pharma SA has presented promising preclinical data of its tetraspecific antibody-based B and NK cell engager IPH6501, a novel approach to treat B cell non-Hodgkin lymphoma (B-NHL). more ➔
AdaptimmuneClinical trialsAdaptimmune nears second approval for TCR-T therapyAfter meeting the primary endpoints of a pivotal Phase II trial, UK-based Adaptimmune Ltd. is submitting an FDA Biologics License Application for its autologous T-cell receptor therapy (TCR-T) Lete-cel … more ➔
Qiagen NVHorizion EuropePharmahungary Group participates in ambitious EU EVEREST Project Pharmahungary Group has announced it will be participating in a project aiming to set up standardised methods to examine intercellular and interorgan communication via extracellular vesicles, the next … more ➔
Alentis TherapeuticsFinancingAlentis Therapeutics raises US$181.4m in Series D financingSwiss Alentis Therapeutics has raised US$181.4m in an oversubscribed Series D financing set to boost clinical development of its anti-Claudin-1 ADCs in solid tumours. more ➔
BIOCOMPEGS Europe 2024Next-gen antibody formats presented at PEGS EuropeBiotech CSOs, CDMOs, CROs, lab specialists and AI developers gave an in-depth insight into next-generation antibody-based therapies to about 1,500 attendees at the 16th PEGS Europe in Barcelona. Several … more ➔
Memorial Sloan Kettering Cancer CentreEarly cancer detectionHarbinger Health to speed up clinical cancer test validationUS spin-out of German MPI for molecular genetics, Harbinger Health Inc, has started a collaboration with Memorial Sloan Kettering Cancer Centre to turboboost recruiting for its Core-HH study. The study … more ➔
Novo NordiskCollaborationNovo Nordisk signs deal for monthly GLP-1 agonistNovo Nordisk is putting down up to US$362m to tap into Ascendis’ TransCon technology for treatments in metabolic and cardiovascular diseases. The pharma powerhouse has its sights set on developing … more ➔
ProBioGenCancer vaccinesTransgene and ProBioGen forge partnershipThe Strasbourg-based biotech company Transgene and the Berlin-based CDMO ProBioGen have entered into a licensing agreement to collaboratively advance the development of individualised cancer vaccine … more ➔
By Benff - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=128081038Novo NordiskNovo’s obesity blockbuster semaglutide before label extensionIn both, liver fibrosis and resolution of MASH, Novo Nordisk’s GLP1 modulator semaglutide has shown convincing results in the Phase III ESSENCE study suggesting a label extension of the obesity bloc … more ➔
Innate Pharma SA
Adaptimmune
Qiagen NV
Alentis Therapeutics
BIOCOM
Memorial Sloan Kettering Cancer Centre
Novo Nordisk
ProBioGen
By Benff - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=128081038